Sutro Biopharma, Inc. (STRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
STRO POWR Grades
- STRO scores best on the Growth dimension, with a Growth rank ahead of 88.87% of US stocks.
- The strongest trend for STRO is in Quality, which has been heading up over the past 178 days.
- STRO's current lowest rank is in the Momentum metric (where it is better than 9.24% of US stocks).
STRO Stock Summary
- STRO's went public 4.48 years ago, making it older than only 21.13% of listed US stocks we're tracking.
- Price to trailing twelve month operating cash flow for STRO is currently 51.44, higher than 91.94% of US stocks with positive operating cash flow.
- Of note is the ratio of SUTRO BIOPHARMA INC's sales and general administrative expense to its total operating expenses; merely 15.61% of US stocks have a lower such ratio.
- Stocks that are quantitatively similar to STRO, based on their financial statements, market capitalization, and price volatility, are BPMC, DTIL, MRKR, CDAK, and FUSN.
- STRO's SEC filings can be seen here. And to visit SUTRO BIOPHARMA INC's official web site, go to www.sutrobio.com.
STRO Valuation Summary
- In comparison to the median Healthcare stock, STRO's price/sales ratio is 126.32% higher, now standing at 4.3.
- STRO's price/earnings ratio has moved up 14.7 over the prior 54 months.
Below are key valuation metrics over time for STRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STRO | 2023-03-17 | 4.3 | 1.3 | -2.4 | -2.2 |
| STRO | 2023-03-16 | 4.3 | 1.3 | -2.5 | -2.2 |
| STRO | 2023-03-15 | 4.4 | 1.4 | -2.5 | -2.3 |
| STRO | 2023-03-14 | 4.5 | 1.4 | -2.6 | -2.4 |
| STRO | 2023-03-13 | 4.5 | 1.4 | -2.5 | -2.3 |
| STRO | 2023-03-10 | 4.2 | 1.3 | -2.4 | -2.2 |
STRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STRO has a Quality Grade of D, ranking ahead of 10.85% of graded US stocks.
- STRO's asset turnover comes in at 0.194 -- ranking 205th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows STRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.194 | 1 | -0.301 |
| 2021-03-31 | 0.150 | 1 | -0.169 |
| 2020-12-31 | 0.151 | 1 | -0.155 |
| 2020-09-30 | 0.204 | 1 | 0.118 |
| 2020-06-30 | 0.212 | 1 | -0.081 |
| 2020-03-31 | 0.246 | 1 | -0.444 |
STRO Price Target
For more insight on analysts targets of STRO, see our STRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.38 (Strong Buy) |
STRO Stock Price Chart Interactive Chart >
STRO Price/Volume Stats
| Current price | $5.11 | 52-week high | $9.59 |
| Prev. close | $5.22 | 52-week low | $3.33 |
| Day low | $4.97 | Volume | 595,100 |
| Day high | $5.21 | Avg. volume | 525,485 |
| 50-day MA | $6.53 | Dividend yield | N/A |
| 200-day MA | $6.27 | Market Cap | 293.70M |
Sutro Biopharma, Inc. (STRO) Company Bio
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.
Latest STRO News From Around the Web
Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors (i) granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units (RSUs) of Sutro common stock in connection with her a |
Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this yearLooking at Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) insider transactions over the last year, we can see that insiders... |
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA. The presentation will be acce |
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S. |
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the... |
STRO Price Returns
| 1-mo | -17.85% |
| 3-mo | -27.00% |
| 6-mo | -2.29% |
| 1-year | -35.88% |
| 3-year | -37.45% |
| 5-year | N/A |
| YTD | -36.76% |
| 2022 | -45.70% |
| 2021 | -31.46% |
| 2020 | 97.36% |
| 2019 | 21.95% |
| 2018 | N/A |
Continue Researching STRO
Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...